Drug Discovery & Pharmaceuticals

RSS

Avacta and Daewoong Pharmaceutical announce joint venture to develop novel cell and gene therapies

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, and Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, are pleased to announce that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.

From Avacta Life Sciences Ltd. 9 Jan 2020

Novel study on molecular interactions could make it easier to develop new medicines

A first-of-its-kind study on molecular interactions by biomedical engineers in the University of Minnesota's College of Science and Engineering will make it easier and more efficient for scientists to develop new medicines and other therapies for diseases such as cancer, HIV, and autoimmune diseases.

3 Jan 2020

Studying Alzheimer’s and Parkinson’s Disease using Pre-Formed Fibrils

Ariel Louwrier discusses the development of pre-formed tau and alpha-synuclein fibrils for research into Alzheimer's and Parkinson's disease.

From StressMarq Biosciences Inc. 2 Jan 2020

Scientists identify molecules capable of inhibiting DNA methylation, effectively killing malaria parasites

Parasites in the genus Plasmodium, which cause malaria, are transmitted to humans through bites from infected mosquitoes.

31 Dec 2019

NIH awards $1.2 million grant for studying biomolecular interactions to inform better drug design

Biomolecules -- carbohydrates, proteins, nucleic acids, and lipids -- form the foundation of life and are responsible for carrying out every process that occurs in our bodies.

23 Dec 2019

Developing less aggressive cancer drugs that enable the immune system to recognize tumors

Doctors treat tumors mainly through surgery, radiotherapy, and chemotherapy. Over the next four years, a new project of Bielefeld University and 14 European partners will be studying targeted cancer treatments.

21 Dec 2019

New 'tumor-on-a-chip' can be used to find better cancer fighting drugs

Kyoto University researchers have developed a new 'tumor-on-a-chip' device that can better mimic the environment inside the body, paving the way for improved screening of potential cancer-fighting drugs.

20 Dec 2019

Researchers discover new way to supercharge protein production

Medicines such as insulin for diabetes and clotting factors for hemophilia are hard to synthesize in the lab. Such drugs are based on therapeutic proteins, so scientists have engineered bacteria into tiny protein-making factories.

18 Dec 2019

ELRIG UK and British Pharmacological Society form strategic alliance to improve education, drive drug discovery

The European Laboratory Research & Innovation Group UK and the British Pharmacological Society, announced today that they have formed a strategic alliance.

17 Dec 2019

Scientists modify approved cancer drug to develop new antibiotic

Antibiotic-resistant bacteria are increasingly the source of deadly infections. A team of scientists from the Technical University of Munich and the Helmholtz Center for Infection Research in Braunschweig have now modified an approved cancer drug to develop an active agent against multidrug-resistant pathogens.

16 Dec 2019

Human genetics evidence predictive of drug development success, study shows

A new drug candidate is more likely to be approved for use if it targets a gene known to be linked to the disease; a finding that can help pharmaceutical companies to focus their drug development efforts.

From PLOS ONE 13 Dec 2019

Quick and simple method for identifying illicit drugs in powdered mixtures

The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation, according to a new study published in the journal Angewandte Chemie.

11 Dec 2019

IONTAS antibody for the treatment of B-Cell ALL receives approval for clinical trials

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has been informed that International Biotechnology Center Generium, a leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia.

From FairJourney Biologics 11 Dec 2019

US pharmaceutical industry continues to shine according to CPhI 2019 Annual Report

The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceutical industry executives published as part of the recently released CPhI 2019 Annual Report.

From LabVantage Solutions 6 Dec 2019

FlowSyn flow chemistry system enables economic and green manufacture of active pharmaceutical ingredients

Uniqsis has recently installed a 4-channel FlowSyn flow chemistry system in the Riley Research Group Laboratories at the University of Pretoria (South Africa).

From Uniqsis Ltd 6 Dec 2019

New method to improve skeleton of common chemicals

Every chemical, from the simplest to the most complex, have a structural skeleton of atoms. The atoms can be added or removed to transform the chemical into different types, for use in different applications. For many pharmaceutical and agricultural chemicals, the skeleton consists of a multi-membered carbon ring called a carbocycle.

5 Dec 2019

GW-led consortium receives $2.2 million from FDA for Biocompute Object Specification Project

A consortium led by the George Washington University (GW) has been refunded for their BioCompute Object Specification Project, thanks to a $2.2 million, five-year grant from the U.S. Food and Drug Administration.

4 Dec 2019

LUNAC-led drug discovery project receives funding under Innovate UK’s Biomedical Catalyst program

LUNAC Therapeutics, a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced that, along with the Medicines Discovery Catapult and the University of Leeds, it has been awarded £3.14M funding under Innovate UK’s Biomedical Catalyst program.

4 Dec 2019

Metrion and LifeArc extend neuroscience-focused ion channel drug discovery collaboration

Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced an extension of their neuroscience-focused ion channel drug discovery collaboration, following the success of the initial twelve-month agreement.

From Metrion Biosciences Limited 4 Dec 2019

IONTAS, Adaptate Biotherapeutics join forces to generate and optimize antibodies for novel cancer targets

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

From FairJourney Biologics 4 Dec 2019